Acurx Pharmaceuticals Inc (NASDAQ: ACXP) is developing novel antibiotics to treat bacterial infections, announced the data from Phase I trial, and indicated a lower risk of recurrence of Clostridioides difficile Infection (CDI) with Ibezapolstat in comparison to Vancomycin. Commencing Phase 2 trial: After the success of Phase I, Acurx Pharmaceuticals is […]